Streetbeat News

RNXT

RenovoRx, Inc.

https://renovorx.com

Industry

Biotechnology

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Open

1.10

Mkt cap

27M

Volume

27K

High

1.13

P/E Ratio

-1.88

52-wk high

2.35

Low

1.04

Div yield

N/A

52-wk low

0.53

Northwell Health Cancer Institute has joined RenovoRx's Phase III TIGeR-PaC clinical trial, aiming for full patient enrollment by mid-2025.

Portfolio Pulse from

November 20, 2024 | 2:00 pm

RenovoRx reported its Q3 2024 financial results, highlighting the commercialization plan for its FDA-cleared RenovoCath Delivery System. The company is progressing with its Phase III TIGeR-PaC clinical trial and has $9.6 million in cash to support operations and commercialization efforts.

Portfolio Pulse from

November 14, 2024 | 1:15 pm

RenovoRx is ramping up production of its FDA-cleared RenovoCath Delivery System due to increased demand from oncology and interventional radiology physicians. The company is expanding its partnership with Medical Murray and issuing warrants for manufacturing milestones.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:33 pm

RenovoRx, Inc. (NASDAQ:RNXT) will present its TAMP therapy for locally advanced pancreatic cancer at the Symposium on Clinical Interventional Oncology. The presentation will cover the TAMP platform's potential benefits over standard chemotherapy and the status of the Phase III TIGeR-PaC study.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 12:42 pm

Top Wall Street analysts have updated their price targets for several companies, including Exact Sciences, Docebo, RenovoRx, Instil Bio, Domino's Pizza, Aramark, TransUnion, Advance Auto Parts, American Tower, and Alcon. Notably, Exact Sciences saw a significant price target increase from Piper Sandler, leading to a 9.8% rise in its stock price.

Portfolio Pulse from Avi Kapoor

September 12, 2024 | 12:21 pm

Ascendiant Capital's analyst Edward Woo maintains a Buy rating on RenovoRx and raises the price target from $8 to $8.25.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 10:00 am

RenovoRx has announced the enrollment of the first patient at the University of Nebraska Medical Center for its pivotal Phase III TIGeR-PaC clinical trial.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 12:35 pm

RenovoRx has published positive early-stage data on its TAMP therapy for locally advanced pancreatic cancer. The therapy, combined with prior chemoradiation, shows a 27-month overall survival rate. An ongoing Phase III trial is evaluating the targeted chemotherapy delivery. The study was published in The Oncologist.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 12:41 pm

The University of Nebraska Medical Center will enroll patients for RenovoRx's Phase III TIGeR-PaC clinical trial, which is focused on treating pancreatic cancer.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 12:34 pm

Ascendiant Capital has initiated coverage on RenovoRx (NASDAQ:RNXT) with a Buy rating and set a price target of $8.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 11:00 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.